IP Verse

Terminally Modified Rna - EP2922554

The patent EP2922554 was granted to Moderna on Feb 23, 2022. The application was originally filed on Oct 2, 2013 under application number EP13779667A. The patent is currently recorded with a legal status of "Revoked".

EP2922554

MODERNA
Application Number
EP13779667A
Filing Date
Oct 2, 2013
Status
Revoked
Jul 4, 2025
Grant Date
Feb 23, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

WITHERS & ROGERSNov 23, 2022GRAF VON STOSCHADMISSIBLE

Patent Citations (108) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2012US58519-
DESCRIPTIONWO2013US31821-
DESCRIPTIONEP2112235
DESCRIPTIONEP2610340
DESCRIPTIONEP2610341
DESCRIPTIONUS2005059005
DESCRIPTIONUS2005261218
DESCRIPTIONUS2007048776
DESCRIPTIONUS2007117112
DESCRIPTIONUS2009092974
DESCRIPTIONUS2009093049
DESCRIPTIONUS2009131348
DESCRIPTIONUS2009226470
DESCRIPTIONUS2009227660
DESCRIPTIONUS2009263803
DESCRIPTIONUS2010120024
DESCRIPTIONUS2010129877
DESCRIPTIONUS2010286232
DESCRIPTIONUS2010293625
DESCRIPTIONUS2010323357
DESCRIPTIONUS2011124100
DESCRIPTIONUS2011171646
DESCRIPTIONUS2011247090
DESCRIPTIONUS2012053224
DESCRIPTIONUS2012214699
DESCRIPTIONUS2012264626
DESCRIPTIONUS2012283310
DESCRIPTIONUS2012309645
DESCRIPTIONUS2012316081
DESCRIPTIONUS2012329672
DESCRIPTIONUS2013042333
DESCRIPTIONUS2013053263
DESCRIPTIONUS2013053264
DESCRIPTIONUS2013059015
DESCRIPTIONUS2013115272
DESCRIPTIONUS2013156849
DESCRIPTIONUS2013177581
DESCRIPTIONUS5208020
DESCRIPTIONUS5475092
DESCRIPTIONUS5585499
DESCRIPTIONUS5846545
DESCRIPTIONUS6310197
DESCRIPTIONUS6849405
DESCRIPTIONUS7183395
DESCRIPTIONUS7374930
DESCRIPTIONUS7385034
DESCRIPTIONUS7413875
DESCRIPTIONUS7456273
DESCRIPTIONUS7468275
DESCRIPTIONUS8101385
DESCRIPTIONUS8124379
DESCRIPTIONUS8252538
DESCRIPTIONUS8389210
DESCRIPTIONUS8415096
DESCRIPTIONUS8519110
DESCRIPTIONWO0155369
DESCRIPTIONWO0155371
DESCRIPTIONWO2007025008
DESCRIPTIONWO2007081740
DESCRIPTIONWO2008054828
DESCRIPTIONWO2008073915
DESCRIPTIONWO2008078180
DESCRIPTIONWO2008154098
DESCRIPTIONWO2009070653
DESCRIPTIONWO2009075886
DESCRIPTIONWO2009100430
DESCRIPTIONWO2010018563
DESCRIPTIONWO2011028175
DESCRIPTIONWO2011076142
DESCRIPTIONWO2011076143
DESCRIPTIONWO2011095623
DESCRIPTIONWO2011157294
DESCRIPTIONWO2012009644
DESCRIPTIONWO2012019168
DESCRIPTIONWO2012045075
DESCRIPTIONWO2012045082
DESCRIPTIONWO2012151212
DESCRIPTIONWO2013011378
DESCRIPTIONWO2013033640
DESCRIPTIONWO2013052523
DESCRIPTIONWO2013066678
DESCRIPTIONWO2013090648
DESCRIPTIONWO2013103659
DESCRIPTIONWO2013109713
DESCRIPTIONWO2013120497
DESCRIPTIONWO2013120498
DESCRIPTIONWO2013120499
DESCRIPTIONWO2013120500
DESCRIPTIONWO2013120626
DESCRIPTIONWO2013120627
DESCRIPTIONWO2013120628
DESCRIPTIONWO2013120629
DESCRIPTIONWO9924595
INTERNATIONAL-SEARCH-REPORTUS2012251618
INTERNATIONAL-SEARCH-REPORTWO2011012316
INTERNATIONAL-SEARCH-REPORTWO2012009644
INTERNATIONAL-SEARCH-REPORTWO2012019168
INTERNATIONAL-SEARCH-REPORTWO2012019630
INTERNATIONAL-SEARCH-REPORTWO2012045075
INTERNATIONAL-SEARCH-REPORTWO2013090648
OPPOSITIONUS2006058266
OPPOSITIONWO2007024708
OPPOSITIONWO2010098861
OPPOSITIONWO2011005799
OPPOSITIONWO2011068810
OPPOSITIONWO2012019780
OPPOSITIONWO2013090648
OTHERWO2011068810

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- LILI YANG ET AL, "miR-146a controls the resolution of T cell responses in mice", THE JOURNAL OF EXPERIMENTAL MEDICINE, US, (20120827), vol. 209, no. 9, doi:10.1084/jem.20112218, ISSN 0022-1007, pages 1655 - 1670, XP055594915
EXAMINATION- A. ANNONI ET AL, "In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance", BLOOD, (20091210), vol. 114, no. 25, doi:10.1182/blood-2009-04-214569, ISSN 0006-4971, pages 5152 - 5161, XP055085822
OPPOSITION- BROWN B D, NALDINI L., "Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications.", NATURE REVIEWS GENETICS, MACMILLAN MAGAZINES, GB, GB , (20090801), vol. 10, no. 8, pages 578 - 585, XP002607892-
OPPOSITION- Jennifer L. Clancy, Marco Nousch, David T. Humphreys, Belinda J. Westman, Traude H. Beilharz, Thomas Preiss, "Methods to Analyze MicroRNA‐Mediated Control of mRNA Translation", METHODS IN ENZYMOLOGY. Vol 431, Elsevier , (20070101), pages 83 - 111, XP055743484-
OPPOSITION- Kuhn Andreas N; Beissert Tim; Simon Petra; Vallazza Britta; Buck Janina; Davies Brian P; Tuereci Oezlem; Sahin Ugur, "mRNA as a Versatile Tool for Exogenous Protein Expression", Current Gene Therapy, Bentham Science Publishers Ltd., NL, NL , (20121001), vol. 12, no. 5, ISSN 1566-5232, pages 347 - 361, XP008159357-
OPPOSITION- Steve Pascolo, "Chapter 7.2. Plasmid DNA and Messenger RNA for Therapy", Steve Pascolo, Shayne Cox, Steve Pascolo, Handbook of Pharmaceutical Biotechnology, John Wiley & Sons , (20070601), pages 971 - 1011, doi:10.1002/9780470117118.ch07b, ISBN 978-0-471-21386-4, XP055626043
OPPOSITION- Sebastian Kreiter, Mustafa Diken, Abderraouf Selmi, Özlem Türeci, Ugur Sahin, "Tumor vaccination using messenger RNA: prospects of a future therapy", Current Opinion in Immunology, Elsevier Current Trends, (20110601), vol. 23, no. 3, doi:10.1016/j.coi.2011.03.007, ISSN 09527915, pages 399 - 406, XP055018902
OPPOSITION- Jeffrey B. Ulmer; Peter W. Mason; Andrew Geall; Christian W. Mandl;, "RNA-based vaccines", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20120418), vol. 30, no. 30, doi:10.1016/j.vaccine.2012.04.060, ISSN 0264-410X, pages 4414 - 4418, XP028520925
OPPOSITION- Xingfang Su, Jennifer Fricke, Daniel G. Kavanagh, Darrell J. Irvine, "In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles", Molecular Pharmaceutics, American Chemical Society, (20110606), vol. 8, no. 3, doi:10.1021/mp100390w, ISSN 15438384, pages 774 - 787, XP055127583
OPPOSITION- KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.", Molecular Therapy, Nature Publishing Group, GB, GB , (20081101), vol. 16, no. 11, doi:10.1038/mt.2008.200, ISSN 1525-0024, pages 1833 - 1840, XP002598556
OPPOSITION- Wang Yuhua; Su Hsing-Hao; Yang Yang; Hu Yunxia; Zhang Lu; Blancafort Pilar; Huang Leaf, "Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.", Molecular Therapy, Nature Publishing Group, GB, GB , (20130201), vol. 21, no. 2, doi:10.1038/mt.2012.250, ISSN 1525-0024, pages 358 - 367, XP009170717
OPPOSITION- Karikó K, Muramatsu H, Keller J M, Weissman D., "Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.", Molecular Therapy, Nature Publishing Group, GB, GB , (20120501), vol. 20, no. 5, doi:10.1038/mt.2012.7, ISSN 1525-0024, pages 948 - 953, XP002696191
OPPOSITION- Coulouarn C, Factor V M, Andersen J B, Durkin M E, Thorgeirsson S S, "Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties /NIH Author Manuscript/", Oncogene, Nature Publishing Group UK, London, London , (20091008), vol. 28, no. 40, doi:10.1038/onc.2009.211, ISSN 0950-9232, pages 3526 - 3536, XP093005532
OPPOSITION- B. R. Anderson, H. Muramatsu, S. R. Nallagatla, P. C. Bevilacqua, L. H. Sansing, D. Weissman, K. Kariko, "Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation", Nucleic Acids Research, Information Retrieval Ltd., (20100901), vol. 38, no. 17, doi:10.1093/nar/gkq347, ISSN 03051048, pages 5884 - 5892, XP055041208
OPPOSITION- Katalin Karikó, Hiromi Muramatsu, János Ludwig, and Drew Weissman, "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.", Nucleic Acids research, Oxford University Press, GB, GB , (20111101), vol. 39, no. 21, doi:10.1093/nar/gkr695, ISSN 1362-4962, pages e142-1 - e142-10, XP002696190
OPPOSITION- Del Pozo-Rodriguez Ana, Delgado Diego, A. Solinis Maria, R. Gascon Alicia, "Lipid Nanoparticles as Vehicles for Macromolecules: Nucleic Acids and Peptides", RECENT PATENTS ON DRUG DELIVERY & FORMULATION, Bentham Science Publishers Ltd., NL, NL , (20110901), vol. 5, no. 3, doi:10.2174/187221111797200515, ISSN 1872-2113, pages 214 - 226, XP093005538
OPPOSITION- Jopling Catherine, "Liver-specific microRNA-122: Biogenesis and function", RNA BIOLOGY, (20120201), vol. 9, no. 2, doi:10.4161/rna.18827, ISSN 1547-6286, pages 137 - 142, XP093005486

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents